Biontech stock price hovers at $91

BioNTech stock price hovers at $91.09, with short-term trend lines indicating consolidation before a likely breakout pattern. Investor focus is partly on macro vaccine deployment trends influencing quarterly cash flows. It had previously cut jobs as it sought to move beyond its failure to develop an mRNA-based COVID vaccine during the pandemic. Most importantly, it acquired a bispecific antibody targeting the proteins PD-L1 and VEG-F. That technology promises to build on – and possibly best – the success that Merck has found with Keytruda, a cancer drug with nearly $30 billion in sales last year alone. BioNTech stock price holds firm at $90.97, supported by steady institutional purchases over the past week. This sustained demand in the biotech sector may signal stronger long-term conviction despite short-term volatility.